Interactive Financial Charts Not Available

Strides Pharma (STAR) | Financial Analysis & Statements

Strides Pharma Science Ltd. | Mid-cap | Healthcare

₹803.50

0.82%

Strides Pharma vs Sun Pharmaceutical Strides Pharma vs Divi's Laboratories Strides Pharma vs Alembic Strides Pharma vs Jubilant Pharmova Strides Pharma vs Natco Pharma Strides Pharma vs NIFTY 50 | Market

TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 11.2B

Gross Profit 6.8B 60.32%

Operating Income 1.7B 15.11%

Net Income 1.1B 9.43%

EPS (Diluted) ₹10.81

Balance Sheet Metrics

Total Assets 60.5B

Total Liabilities 34.6B

Shareholders Equity 25.9B

Debt to Equity 1.34

Cash Flow Metrics

Revenue & Profitability Trend

Interactive Financial Charts Not Available

This page uses interactive financial charts and dynamic data visualization tools that require JavaScript. For detailed financial analysis:

Available Financial Data:

Income statements (annual and quarterly)
Balance sheets with asset and liability details
Cash flow statements and free cash flow analysis
Key financial ratios and performance metrics
Peer comparison and industry benchmarking

All financial data is displayed in accessible table format below. Use the table headers and structure to analyze trends and compare metrics across different periods.

Strides Pharma Income Statement From 2021 to 2025

Metric	2025	2024	2023	2022	2021
Revenue i	43.9B	38.9B	36.1B	30.2B	32.5B
Cost of Goods Sold i	21.3B	17.3B	17.0B	15.8B	14.1B
Gross Profit i	22.6B	21.7B	19.1B	14.4B	18.4B
Gross Margin % i	51.4%	55.7%	52.9%	47.6%	56.7%
Operating Expenses
Research & Development i	-	-	-	-	-
Selling, General & Administrative i	4.2B	3.8B	4.1B	4.8B	3.4B
Other Operating Expenses i	3.3B	4.5B	4.4B	3.6B	3.8B
Total Operating Expenses i	7.6B	8.3B	8.6B	8.4B	7.2B
Operating Income i	5.8B	4.8B	1.4B	-2.4B	4.2B
Operating Margin % i	13.2%	12.4%	4.0%	-8.0%	13.0%
Non-Operating Items
Interest Income i	453.7M	296.4M	745.1M	1.1B	353.0M
Interest Expense i	2.1B	2.7B	2.2B	1.5B	1.3B
Other Non-Operating Income	-	-	-	-	-
Pre-tax Income i	4.9B	-1.2B	-2.9B	-6.5B	2.8B
Income Tax i	775.2M	315.9M	-553.0M	-1.8B	316.5M
Effective Tax Rate % i	15.9%	0.0%	0.0%	0.0%	11.5%
Net Income i	36.0B	-943.1M	-2.1B	-4.7B	2.6B
Net Margin % i	81.9%	-2.4%	-5.9%	-15.7%	7.9%
Key Metrics
EBITDA i	7.9B	5.3B	1.9B	-384.9M	5.6B
EPS (Basic) i	₹390.55	₹-7.76	₹-22.49	₹-51.28	₹29.96
EPS (Diluted) i	₹390.50	₹-7.76	₹-22.49	₹-51.28	₹29.92
Basic Shares Outstanding i	92011241	91001818	90080778	89747525	89609605
Diluted Shares Outstanding i	92011241	91001818	90080778	89747525	89609605

Income Statement Trend

Strides Pharma Balance Sheet From 2021 to 2025

Metric	2025	2024	2023	2022	2021
Assets
Current Assets
Cash & Equivalents i	1.1B	1.6B	3.0B	1.7B	1.3B
Short-term Investments i	860.6M	1.3B	572.0M	134.6M	1.5B
Accounts Receivable i	12.0B	11.4B	13.0B	12.1B	11.1B
Inventory i	12.8B	11.3B	11.5B	11.7B	12.0B
Other Current Assets	2.3B	2.7B	2.2B	2.0B	2.1B
Total Current Assets i	31.0B	29.7B	32.5B	33.6B	28.2B
Non-Current Assets
Property, Plant & Equipment i	8.8B	8.8B	13.2B	14.6B	12.7B
Goodwill i	16.6B	15.9B	15.9B	16.0B	15.8B
Intangible Assets i	5.7B	5.3B	5.6B	6.2B	6.2B
Long-term Investments	25.1M	14.7M	0	-	-
Other Non-Current Assets	443.2M	242.5M	265.3M	104.8M	249.5M
Total Non-Current Assets i	29.5B	28.7B	33.9B	36.1B	42.0B
Total Assets i	60.5B	58.4B	66.4B	69.8B	70.2B
Liabilities
Current Liabilities
Accounts Payable i	10.3B	8.5B	9.8B	10.7B	11.3B
Short-term Debt i	12.6B	17.7B	16.9B	20.0B	12.6B
Current Portion of Long-term Debt	-	-	-	-	-
Other Current Liabilities	800.8M	689.2M	764.8M	30.4M	643.8M
Total Current Liabilities i	25.9B	28.8B	29.9B	34.1B	27.4B
Non-Current Liabilities
Long-term Debt i	6.2B	7.4B	13.4B	10.2B	10.9B
Deferred Tax Liabilities i	1.2B	403.4M	445.7M	357.2M	463.5M
Other Non-Current Liabilities	-	-	18.3M	16.0M	1.1M
Total Non-Current Liabilities i	8.7B	8.9B	14.8B	11.8B	14.6B
Total Liabilities i	34.6B	37.7B	44.7B	45.9B	42.0B
Equity
Common Stock i	921.6M	919.0M	903.0M	897.9M	896.8M
Retained Earnings i	4.6B	-2.8B	-2.0B	23.1M	4.8B
Treasury Stock i	-	-	-	-	-
Other Equity	-	-	-	-	-
Total Shareholders Equity i	25.9B	20.7B	21.7B	23.8B	28.1B
Key Metrics
Total Debt i	18.8B	25.2B	30.3B	30.3B	23.5B
Working Capital i	5.1B	932.3M	2.6B	-472.7M	814.6M

Balance Sheet Composition

Strides Pharma Cash Flow Statement From 2021 to 2025

Metric	2025	2024	2023	2022	2021
Operating Activities
Net Income i	36.8B	-627.2M	-2.7B	-6.5B	2.9B
Depreciation & Amortization i	-	-	-	-	-
Stock-Based Compensation i	16.1M	15.9M	13.0M	-7.1M	68.0M
Working Capital Changes i	-2.7B	697.9M	-3.6B	-306.1M	-5.4B
Operating Cash Flow i	36.0B	2.9B	-4.9B	-5.7B	-563.6M
Investing Activities
Capital Expenditures i	681.0M	888.1M	72.6M	753.7M	39.6M
Acquisitions i	-78.8M	7.9M	5.2B	-2.2B	-78.9M
Investment Purchases i	-83.5M	-863.9M	-1.6B	-591.7M	-2.8B
Investment Sales i	415.3M	18.0M	191.5M	2.2B	422.4M
Investing Cash Flow i	955.0M	68.0M	3.9B	179.1M	-2.3B
Financing Activities
Share Repurchases i	-	-	-	-	-
Dividends Paid i	-229.9M	-135.2M	-	-224.3M	-179.2M
Debt Issuance i	1.3B	1.1B	3.3B	4.5B	5.7B
Debt Repayment i	-3.2B	-7.3B	-2.6B	-2.7B	-2.1B
Financing Cash Flow i	-3.7B	-3.5B	634.0M	6.2B	1.6B
Free Cash Flow i	4.4B	5.8B	-505.3M	-4.0B	1.8B
Net Change in Cash i	33.3B	-498.8M	-334.6M	695.6M	-1.3B

Cash Flow Trend

Strides Pharma Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 21.59

Forward P/E 12.43

Price to Book 2.89

Price to Sales 1.59

PEG Ratio 12.43

Profitability Ratios

Profit Margin 7.38%

Operating Margin 15.11%

Return on Equity 138.93%

Return on Assets 59.41%

Financial Health

Current Ratio 1.20

Debt to Equity 72.67

Beta 0.57

Per Share Data

EPS (TTM) ₹37.06

Book Value per Share ₹276.88

Revenue per Share ₹502.96

Peer Financial Comparison

Company	Market Cap	P/E Ratio	P/B Ratio	ROE	Profit Margin	Debt/Equity
star	73.7B	21.59	2.89	138.93%	7.38%	72.67
Sun Pharmaceutical	3.9T	37.37	5.42	15.08%	19.29%	3.26
Divi's Laboratories	1.6T	70.40	10.87	14.64%	23.89%	0.03
Alembic	184.0B	30.50	3.55	11.24%	8.84%	24.23
Jubilant Pharmova	179.0B	38.96	2.85	13.45%	6.22%	43.78
Natco Pharma	165.3B	8.75	2.17	27.97%	42.57%	3.67

Financial data is updated regularly. All figures are in the company's reporting currency.